Access Resources
6081 - 6090 of 7616 Results
Title
Year
- Pure Autonomic Failure Versus Prodromal Dysautonomia in Parkinson's Disease: Insights from the Bedside2016RESTRICTEDTitle: Pure Autonomic Failure Versus Prodromal Dysautonomia in Parkinson's Disease: Insights from the BedsideJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 4Issue #: 1Start Page: 141End Page: 144Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12360Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12360Citation Count: 11
- Dentate nucleus iron deposition is a potential biomarker for tremor‐dominant Parkinson's disease2016RESTRICTEDTitle: Dentate nucleus iron deposition is a potential biomarker for tremor‐dominant Parkinson's diseaseJournal Name: NMR in BiomedicinePublisher: WileyVol: 30Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/nbm.3554Best OA location URL: https://europepmc.org/articles/pmc4906439?pdf=renderCitation Count: 43
-
RESTRICTEDTitle: Predictors of time to initiation of symptomatic therapy in early Parkinson's diseaseJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 3Issue #: 7Start Page: 482End Page: 494Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.317Best OA location URL: https://doi.org/10.1002/acn3.317Citation Count: 23
-
RESTRICTEDTitle: Neurogenesis in Cancun: where science meets the seaJournal Name: DevelopmentPublisher: The Company of BiologistsVol: 143Issue #: 10Start Page: 1649End Page: 1654Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1242/dev.138412Best OA location URL: https://dev.biologists.org/content/develop/143/10/1649.full.pdfCitation Count: 0
-
RESTRICTEDTitle: Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseasesJournal Name: Expert Opinion on Therapeutic TargetsPublisher: Informa UK LimitedVol: 20Issue #: 10Start Page: 1237End Page: 1245Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14728222.2016.1182990Best OA location URL: https://europepmc.org/articles/pmc5315368?pdf=renderCitation Count: 42
- Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analytics2016RESTRICTEDTitle: Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analyticsJournal Name: mHealthPublisher: AME Publishing CompanyVol: 2Issue #:Start Page: 20End Page: 20Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.21037/mhealth.2016.04.02Best OA location URL: https://europepmc.org/articles/pmc5344108?pdf=renderCitation Count: 28
- LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias2016RESTRICTEDTitle: LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesiasJournal Name: Molecular BrainPublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13041-016-0234-2Best OA location URL: https://molecularbrain.biomedcentral.com/track/pdf/10.1186/s13041-016-0234-2Citation Count: 9
-
RESTRICTEDTitle: α‐synuclein genetic variability: A biomarker for dementia in Parkinson diseaseJournal Name: Annals of NeurologyPublisher: WileyVol: 79Issue #: 6Start Page: 991End Page: 999Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/ana.24664Best OA location URL: http://spiral.imperial.ac.uk/bitstream/10044/1/61098/6/Guella_et%20al_2018%2bSuppl.pdfCitation Count: 84
- How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?2016RESTRICTEDTitle: How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?Journal Name: Journal of NeurochemistryPublisher: WileyVol: 139Issue #: S1Start Page: 131End Page: 155Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/jnc.13627Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jnc.13627Citation Count: 81
- Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)2016RESTRICTEDTitle: Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)Journal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 7Issue #: 9Start Page: 1192End Page: 1200Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.6b00035Best OA location URL: https://europepmc.org/articles/pmc5031509?pdf=renderCitation Count: 39